Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals (Nasdaq: ACAD) has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
The webcast will be accessible through Acadia's website investor section and archived until August 6, 2025. Interested participants can register for the conference call to receive dial-in details and a unique PIN.
Acadia specializes in neuroscience breakthroughs and has achieved notable milestones, including developing the first FDA-approved treatment for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved treatment for Rett syndrome in the United States and Canada. Their current clinical-stage research focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuro-psychiatric and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced the granting of inducement awards to twenty-two new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee on April 3, 2025, include:
- Non-qualified stock options to purchase 172,637 shares at $16.12 per share
- 64,791 restricted stock units (RSUs)
The stock options will vest over 4 years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest over 4 years, with 50% vesting at the second anniversary and the remaining in two equal annual installments.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to thirteen new employees under its 2024 Inducement Plan, as approved by the Compensation Committee on March 5, 2025. The awards include:
- 71,981 non-qualified stock options with an exercise price of $18.08 per share
- 42,159 restricted stock units (RSUs)
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining in two equal annual installments.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) has announced its participation in three upcoming virtual investor conferences in March and April 2025. The company will participate in:
- UBS Virtual CNS Day with a fireside chat on March 17, 2025 at 11:00 a.m. ET
- Stifel 2025 Virtual CNS Forum with a fireside chat on March 19, 2025 at 12:30 p.m. ET
- 24th Annual Needham Virtual Healthcare Conference with a fireside chat on April 7, 2025 at 10:15 a.m. ET
All fireside chats will be available via live webcasts on Acadia.com under the investors section, with recordings accessible for approximately one month after each presentation. Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis hallucinations and delusions, as well as the first approved drug for Rett syndrome in the US and Canada. The company's current clinical-stage development focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the publication of clinical data from the open-label DAFFODIL™ study in the journal Med, evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The Phase 2/3 study focused on children aged 2-4 years (n=15) and demonstrated safety profiles consistent with previous LAVENDER™ and LILAC™ studies.
The 78-week study showed diarrhea (80.0%) and vomiting (53.3%) as common side effects, all of mild or moderate severity. Exploratory efficacy endpoints indicated symptom improvements, with Clinical Global Impression-Improvement (CGI-I) scores improving from 3.3 at Week 4 to 2.2 at Week 78. Caregiver interviews reported improvements in verbal communication (71.4%), eye contact (57.1%), and hand use (57.1%).
These results supported FDA and Health Canada approvals of DAYBUE for treating Rett syndrome in patients aged two years and older, marking it as the first approved treatment for this rare neurodevelopmental disorder affecting 6,000 to 9,000 patients in the U.S.
Acadia Pharmaceuticals (ACAD) and Saniona have announced positive results from their Phase 1 multiple-ascending-dose (MAD) study of ACP-711 in healthy volunteers. The study demonstrated that ACP-711 was safe and well-tolerated across all dosing cohorts, with no serious adverse events reported.
Key findings include:
- All participants completed the study
- Most adverse events were mild
- No safety laboratory concerns
- No cardiovascular concerns
- No abnormal neurological findings
Given these favorable results and the prioritization of essential tremor as the lead indication, the companies are seeking regulatory approval to evaluate ACP-711 in elderly healthy volunteers and test higher repeated doses. The study has been temporarily paused pending this regulatory approval.
Acadia Pharmaceuticals (Nasdaq: ACAD) has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company will engage in a fireside chat on Wednesday, March 5, 2025, at 11:10 a.m. Eastern Time.
The presentation will be available through a live webcast on Acadia.com under the investors section, with an archived recording accessible for approximately one month afterward.
Acadia is a neuroscience-focused pharmaceutical company known for developing the first FDA-approved treatment for Parkinson's disease psychosis hallucinations and delusions, as well as the first approved drug in the United States and Canada for Rett syndrome. Their current clinical-stage development pipeline includes programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and various other neuroscience and neuro-rare diseases.
Acadia Pharmaceuticals (ACAD) reported strong financial results for Q4 and full year 2024, with total net product sales reaching $957.8 million, a 32% revenue growth. The company's two main products showed significant performance:
DAYBUE achieved Q4 sales of $96.7M and full-year sales of $348.4M, while NUPLAZID recorded Q4 sales of $162.9M and full-year sales of $609.4M. The company reported a net income of $226.5M for 2024, compared to a net loss of $61.3M in 2023.
For 2025, Acadia projects total revenues between $1.03-$1.095 billion, with NUPLAZID sales guidance of $650-690M and DAYBUE sales guidance of $380-405M. The company's cash position strengthened to $756.0M by end of 2024, up from $438.9M in 2023.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that its Compensation Committee granted inducement awards to eighteen new employees on February 6, 2025. The awards include non-qualified stock options to purchase 171,065 shares of common stock at $19.13 per share and 55,170 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment with Acadia.
The grants were made under Acadia's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Acadia Pharmaceuticals (Nasdaq: ACAD) has scheduled its fourth quarter and full year 2024 financial results announcement for February 26, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
The webcast will be accessible through Acadia's website investor section until May 26, 2025. Participants can register for the conference call to receive dial-in details and a unique PIN. Acadia is known for developing the first FDA-approved drug for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved treatment for Rett syndrome in the United States and Canada. The company's clinical pipeline includes programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuro-psychiatric and neuro-rare diseases.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
